Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential | The Motley Fool
This clinical-stage biotech focuses on developing therapies for neurological and immunoscience disorders.

Source: The Motley Fool
This clinical-stage biotech focuses on developing therapies for neurological and immunoscience disorders.